α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM, exhibiting antidiabetic properties [1].

In a study, α-Glucosidase-IN-18 (7B) administered orally at doses of 10 or 20 mg/kg exhibited antidiabetic properties by significantly lowering blood glucose levels from 392.16 mg/dL in diabetic controls to 112.97 mg/dL at the 20 mg/kg dose after 28 days in male Wistar albino rats with streptozotocin-induced diabetes. This compound also mitigated diabetes-induced weight loss. Additionally, it demonstrated anti-hyperlipidemic effects, reducing total cholesterol levels from 226.03 mg/dL to 136.4 mg/dL, LDL from 183.3 mg/dL to 114.18 mg/dL, and triglycerides from 189.35 mg/dL to 118.61 mg/dL. Furthermore, α-Glucosidase-IN-18 (7B) decreased ALP, SGPT, and SGOT levels, improved renal function by reducing serum creatinine from 3.01 mg/dL to as low as 0.79 mg/dL, and increased insulin levels from 0.369 mg/dL to 0.639 mg/dL, indicating a potential therapeutic effect on various biochemical parameters associated with diabetes [1].